Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy

Area of Science:

• Cell Biology
• Molecular Biology
• Pharmacology

Background:

• Kinesin motor proteins, including Eg5 and HSET, are crucial for cell division and represent promising anticancer targets.
• Eg5 and HSET kinesins have opposing roles in mitotic spindle assembly, offering distinct therapeutic intervention points.
• Targeting these proteins can lead to cancer-selective therapies due to their essential functions in proliferating cells.

Purpose of the Study:

• To review the progress in developing inhibitors for Eg5 and HSET kinesins.
• To highlight structural biology insights into allosteric inhibitor binding, selectivity, and mechanisms of action.
• To discuss the clinical translation of Eg5 inhibitors and future directions in anticancer drug development.

Main Methods:

• Literature review of preclinical and clinical studies on Eg5 and HSET inhibitors.
• Analysis of structural biology data to understand inhibitor binding modes.
• Examination of compound selectivity and chemical scaffold mechanisms.
• Discussion of resistance mechanisms and future therapeutic strategies.

Main Results:

• Significant progress has been made in developing allosteric inhibitors for Eg5 and HSET.
• Structural biology provides key insights into inhibitor binding and selectivity across different chemical scaffolds.
• Clinical experience with Eg5 inhibitors is being translated from preclinical findings.
• Potential resistance mechanisms to these targeted therapies have been identified.

Conclusions:

• Inhibitors of Eg5 and HSET are promising anticancer agents with potential for cancer-selective therapies.
• Structural biology and understanding resistance mechanisms are critical for optimizing drug development.
• Further research into Eg5 and HSET inhibitors holds significant implications for future anticancer drug discovery.